Karen Zaderej - Axogen CEO and President and Director

AXGN Stock  USD 7.77  0.22  2.91%   

CEO

Ms. Karen L. Zaderej is Chairman of the Board, President, Chief Executive Officer of the AxoGen, Inc. She has served as the Chief Executive Officer of Axogens wholly owned subsidiary, Axogen Corporationrationration, and a member of the Board of Directors of Axogen Corporationrationration. Ms. Zaderej joined Axogen Corporation in May 2006 and served as Vice President of Marketing and Sales from May 2006 to October 2007 and as Chief Operating Officer from October 2007 to May 2010. From October 2004 to May 2006, Ms. Zaderej worked for Zaderej Medical Consulting, a consulting firm she founded, which assisted medical device companies in building and executing successful commercialization plans. From 1987 to 2004, Ms. Zaderej worked at Ethicon, Inc., a Johnson Johnson company, where she held senior positions in marketing, business development, research development, as well as ran a manufacturing business. Ms. Zaderej is a Director of Viveve Medical, Inc., a public womens intimate health company and SEBio, a nonprofit supporting the life science industry in the southeastern United States. Ms. Zaderej has an M.B.A. from the Kellogg Graduate School of Business and a B.S. in Chemical Engineering from Purdue University. Ms. Zaderejs qualifications to serve on our Board of Directors include her leadership and depth of knowledge of us, her extensive experience in the medical device industry, and her financial and management expertise. since 2018.
Age 62
Tenure 6 years
Professional MarksMBA
Address 13631 Progress Boulevard, Alachua, FL, United States, 32615
Phone386 462 6800
Webhttps://www.axogeninc.com
Zaderej has an MBA from the Kellogg Graduate School of Business and a BS in Chemical Engineering from Purdue University.

Karen Zaderej Latest Insider Activity

Tracking and analyzing the buying and selling activities of Karen Zaderej against Axogen stock is an integral part of due diligence when investing in Axogen. Karen Zaderej insider activity provides valuable insight into whether Axogen is net buyers or sellers over its current business cycle. Note, Axogen insiders must abide by specific rules, including filing SEC forms every time they buy or sell Axogen'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

Axogen Management Efficiency

The company has return on total asset (ROA) of (0.0684) % which means that it has lost $0.0684 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2208) %, meaning that it created substantial loss on money invested by shareholders. Axogen's management efficiency ratios could be used to measure how well Axogen manages its routine affairs as well as how well it operates its assets and liabilities. As of the 28th of March 2024, Return On Capital Employed is likely to grow to -0.12. In addition to that, Return On Assets is likely to drop to -0.12. At this time, Axogen's Total Assets are very stable compared to the past year. As of the 28th of March 2024, Non Current Assets Total is likely to grow to about 114.3 M, though Non Currrent Assets Other are likely to grow to (83.2 M).
The company currently holds 69.29 M in liabilities with Debt to Equity (D/E) ratio of 0.71, which is about average as compared to similar companies. Axogen Inc has a current ratio of 4.43, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Axogen until it has trouble settling it off, either with new capital or with free cash flow. So, Axogen's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Axogen Inc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Axogen to invest in growth at high rates of return. When we think about Axogen's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 11 records

CEO Age

Deborah TannerLaboratory
52
Timothy WentworthCigna Corp
59
Paul KirchgraberLaboratory
59
Roger MedelMednax Inc
74
Mark OrdanMednax Inc
65
John RatliffLaboratory
58
Gary HuffLaboratory
50
David CordaniCigna Corp
59
James MDMednax Inc
62
Helmy EltoukhyGuardant Health
44
James BoyleLaboratory
58
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 428 people. Axogen Inc (AXGN) is traded on NASDAQ Exchange in USA. It is located in 13631 Progress Boulevard, Alachua, FL, United States, 32615 and employs 426 people. Axogen is listed under Health Care Equipment & Supplies category by Fama And French industry classification.

Management Performance

Axogen Inc Leadership Team

Elected by the shareholders, the Axogen's board of directors comprises two types of representatives: Axogen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Axogen. The board's role is to monitor Axogen's management team and ensure that shareholders' interests are well served. Axogen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Axogen's outside directors are responsible for providing unbiased perspectives on the board's policies.
Gregory Davault, VP Marketing
Mark Friedman, Vice President - Regulatory and Quality
John Engels, Co-Founder and VP
Jamie Grooms, Co-Founder, Chairman, Member of Audit Committee and Member of Governance and Nominating Committee
Shawn McCarrey, Sr. VP of Sales
Kevin Leach, Vice President - Marketing
Joseph Mandato, Independent Director
Mike Donovan, Director of Operations
CFA CPA, Chief Officer
Kaila Krum, Vice President Investor Relations and Corporate Development
Christopher Crisman, Vice President - U.S. Sales
Alan Levine, Director
Guido Neels, Director
Marc Began, General VP
Michael Donovan, Vice Operations
James Grooms, Independent Chairman of the Board
Doris Quackenbush, Vice Sales
Harold Tamayo, Vice Relations
Quentin Blackford, Director
Robert Rudelius, Independent Director
Angelo Scopelianos, Vice President - Research & Development
Peter Mariani, Ex CFO
Maria Martinez, Chief Human Resource Officer
Eric Sandberg, Chief Commercial Officer
Amy Wendell, Director
Erick DeVinney, Vice President of Clinical and Translational Sciences
Lisa Colleran, Director
Karen Zaderej, CEO and President and Director
Isabelle Billet, Chief Strategy and Business Development Officer
Jens Kemp, Chief Officer
Gregory Freitag, Senior Vice President - Business Development, General Counsel, Director
David Hansen, Corporate Controller
Bradley JD, G Officer
Ed Joyce, Director Relations
Jon Gingrich, Chief Commercial Officer
Mark Gold, Independent Director
Ivica MD, Chief Officer

Axogen Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Axogen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Axogen in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Axogen's short interest history, or implied volatility extrapolated from Axogen options trading.

Pair Trading with Axogen

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Axogen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Axogen will appreciate offsetting losses from the drop in the long position's value.

Moving together with Axogen Stock

  0.64MMSI Merit Medical Systems Financial Report 24th of April 2024 PairCorr

Moving against Axogen Stock

  0.7CMAXW CareMaxPairCorr
  0.57CVS CVS Health Corp Financial Report 1st of May 2024 PairCorr
The ability to find closely correlated positions to Axogen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Axogen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Axogen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Axogen Inc to buy it.
The correlation of Axogen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Axogen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Axogen Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Axogen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Axogen Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Axogen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Axogen Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Axogen Inc Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Axogen Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.
Note that the Axogen Inc information on this page should be used as a complementary analysis to other Axogen's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.

Complementary Tools for Axogen Stock analysis

When running Axogen's price analysis, check to measure Axogen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Axogen is operating at the current time. Most of Axogen's value examination focuses on studying past and present price action to predict the probability of Axogen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Axogen's price. Additionally, you may evaluate how the addition of Axogen to your portfolios can decrease your overall portfolio volatility.
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Money Managers
Screen money managers from public funds and ETFs managed around the world
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Bonds Directory
Find actively traded corporate debentures issued by US companies
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Is Axogen's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Axogen. If investors know Axogen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Axogen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.51)
Revenue Per Share
3.708
Quarterly Revenue Growth
0.187
Return On Assets
(0.07)
Return On Equity
(0.22)
The market value of Axogen Inc is measured differently than its book value, which is the value of Axogen that is recorded on the company's balance sheet. Investors also form their own opinion of Axogen's value that differs from its market value or its book value, called intrinsic value, which is Axogen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Axogen's market value can be influenced by many factors that don't directly affect Axogen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Axogen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Axogen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Axogen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.